CHICAGO (Reuters) - Patients who got Eli Lilly and Co's anti-clotting drug prasugrel after a coronary stent procedure had fewer stent-related clots than those on standard drug therapy, an analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback